CoChat

A randomized controlled trial of dihydroartemisinin-piperaquine, artesunate-mefloquine and extended artemether-lumefantrine treatments for malaria in pregnancy on the Thailand-Myanmar border

Open access

The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.

Abstract

Background: Artemisinin and artemisinin-based combination therapy (ACT) partner drug resistance in Plasmodium falciparum have spread across the Greater Mekong Subregion compromising antimalarial treatment. The current 3-day artemether-lumefantrine regimen has been associated with high treatment failure rates in pregnant women. Although ACTs are recommended for treating Plasmodium vivax malaria, no clinical trials in pregnancy have been reported. Methods: Pregnant women with uncomplicated malaria on the Thailand-Myanmar border participated in an open-label randomized controlled trial comparing dihydroartemisinin-piperaquine (DP), artesunate-mefloquine (ASMQ) and a 4-day artemether-lumefantrine regimen (AL + ). The primary endpoint for P. falciparum infections was the PCR-corrected cure rate and for P. vivax infections was recurrent parasitaemia, before delivery or day 63, whichever was longer, assessed by Kaplan-Meier estimate. Results: Between February 2010 and August 2016, 511 pregnant women with malaria (353 P. vivax , 142 P. falciparum , 15 co-infections, 1 Plasmodium malariae ) were randomized to either DP ( n =170), ASMQ ( n =169) or AL + ( n =172) treatments. Successful malaria elimination efforts in the region resulted in premature termination of the trial. The majority of women had recurrent malaria (mainly P. vivax relapses, which are not prevented by these treatments). Recurrence-free proportions (95% confidence interval [95% CI]) for vivax malaria were 20.6% (5.1–43.4) for DP ( n =125), 46.0% (30.9–60.0) for ASMQ ( n =117) and 28.7% (10.0–50.8) for AL + ( n =126). DP and ASMQ provided longer recurrence-free intervals. PCR-corrected cure rates (95% CI) for falciparum malaria were 93.7% (81.6–97.9) for DP ( n =49), 79.6% (66.1–88.1) for AMSQ ( n =55) and 87.5% (74.3–94.2) for AL + ( n =50). Overall 65% (85/130) of P. falciparum infections had Pfkelch13 propeller mutations which increased over time and recrudescence occurred almost exclusively in them; risk ratio 9.42 (95% CI 1.30–68.29). Among the women with falciparum malaria, 24.0% (95% CI 16.8–33.6) had P. vivax parasitaemia within 4 months. Nausea, vomiting, dizziness and sleep disturbance were more frequent with ASMQ. Miscarriage, small-for-gestational-age and preterm birth did not differ significantly among the treatment groups, including first trimester exposures ( n =46). Conclusions: DP was well tolerated and safe, and was the only drug providing satisfactory efficacy for P. falciparum -infected pregnant woman in this area of widespread artemisinin resistance. Vivax malaria recurrences are very common and warrant chloroquine prophylaxis after antimalarial treatment in this area. Trial registration: ClinicalTrials.gov identifier NCT01054248 , registered on 22 January 2010.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s12916-021-02002-8

Cites

37 of 37 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Participant flow in the randomized comparison of DP, ASMQ and AL+. Five hundred twelve did not meet eligibility criteria (underage n = 98, first trimester infection before amendment n = 155 or after amendment but no foetal heart beat visible n = 19, hyperparasitaemia n = 21, foetal demise at time of diagnosis n = 5, imminent labour n = 49, severe anaemia n = 3, very low parasitaemia n = 162). ANC: antenatal clinics, AL+: artemether-lumefantrine extended regimen, ASMQ: artesunate-mefloquine, CBC/biochem: complete blood count and biochemistry, DP: dihydroartemisinin-piperaquine, Pf: Plasmodium falciparum, Pm: Plasmodium malariae, PTB: preterm birth, Pv: Plasmodium vivax, SGA: small for gestational age
Fig. 1 Participant flow in the randomized comparison of DP, ASMQ and AL+. Five hundred twelve did not meet eligibility criteria (underage n = 98, first trimester infection before amendment n = 155 or after amendment but no foetal heart beat visible n = 19, hyperparasitaemia n = 21, foetal demise at time of diagnosis n = 5, imminent labour n = 49, severe anaemia n = 3, very low parasitaemia n = 162). ANC: antenatal clinics, AL+: artemether-lumefantrine extended regimen, ASMQ: artesunate-mefloquine, CBC/biochem: complete blood count and biochemistry, DP: dihydroartemisinin-piperaquine, Pf: Plasmodium falciparum, Pm: Plasmodium malariae, PTB: preterm birth, Pv: Plasmodium vivax, SGA: small for gestational ageCC BY · PubMed Central
Fig. 2 Cumulative proportions of treatment success over time for each arm stratified by malaria species estimated by Kaplan-Meier estimator. a Plasmodium falciparum PCR-corrected treatment success. b Plasmodium vivax treatment success. Black dotted line shows 95% and solid line 90%, which is the efficacy threshold set by the World Health Organization to replace the treatment [3]
Fig. 2 Cumulative proportions of treatment success over time for each arm stratified by malaria species estimated by Kaplan-Meier estimator. a Plasmodium falciparum PCR-corrected treatment success. b Plasmodium vivax treatment success. Black dotted line shows 95% and solid line 90%, which is the efficacy threshold set by the World Health Organization to replace the treatment [3]CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 37 references

Research works printed but not linked: 3

  1. World Health Organization. Guidelines for the treatment of malaria. 3rd ed. Geneva: WHO Press; 2015.
  2. World Health Organization. Methods for surveillance of antimalarial drug efficacy. Geneva: WHO Press; 2009.
  3. World Health Organization. Haemoglobin concentrations for the diagnosis of anaemia and assessment of severity. Geneva: WHO Press; 2011.

Cited by

See all 25

Metadata

Authors
Saito, M., Carrara, V. I., Gilder, M. E., Min, A. M., Tun, N. W., Pimanpanarak, M., Viladpai-nguen, J., Paw, M. K., Haohankhunnatham, W., Konghahong, K., Phyo, A. P., Chu, C., Turner, C., Lee, S. J., Duanguppama, J., Imwong, M., Bancone, G., Proux, S., Singhasivanon, P., White, N. J., Nosten, F., & McGready, R.
Affiliations
  • Mahidol University (TH)
  • University of Geneva (CH)
Corresponding author
McGready, Rose
Venue
BMC Medicine
Published
2021-06-10
Volume
19
Issue
1
Pages
132-132
ISSN
1741-7015 (ISSN-L)
OpenAlex
W3169799909
Cited by
25
References
37
Citations by year
2026: 5 · 2025: 3 · 2024: 5 · 2023: 6 · 2022: 5 · 2021: 1
FWCI
3.68
Type
journal article
Language
en
Open access
Licence
Locations
  • BMC Medicine (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Archive ouverte UNIGE (University of Geneva) (publishedVersion, other-oa)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • Holley Pharmacy
  • Wellcome Trust (220211)
Topics
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Malaria Research and Control
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Phytochemical compounds biological activities
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Pharmaceutical Quality and Counterfeiting
Keywords
malaria in pregnancy, dihydroartemisinin-piperaquine, artesunate-mefloquine, artemether-lumefantrine, Plasmodium falciparum, Plasmodium vivax, antimalarial drug resistance, treatment failure, cure rate, Thai-Myanmar border, Greater Mekong Subregion
MeSH terms
Artesunate, Artemether, Artemether, Lumefantrine Drug Combination, Antimalarials, Myanmar, Drug Therapy, Combination, Female, Humans, Infant, Newborn, Malaria, Piperazines, Pregnancy, Quinolines, Thailand, Mefloquine, Malaria, Falciparum, Artemisinins, Premature Birth

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A randomized controlled trial of dihydroartemisinin-piperaquine, artesunate-mefloquine and extended artemether-lumefantrine treatments for malaria in pregnancy on the Thailand-Myanmar border. https://app.cochat.ai/papers/10.1186/s12916-021-02002-8
The paper
Saito, M., Carrara, V. I., Gilder, M. E., Min, A. M., Tun, N. W., Pimanpanarak, M., Viladpai-nguen, J., Paw, M. K., Haohankhunnatham, W., Konghahong, K., Phyo, A. P., Chu, C., Turner, C., Lee, S. J., Duanguppama, J., Imwong, M., Bancone, G., Proux, S., Singhasivanon, P., . . . McGready, R. (2021). A randomized controlled trial of dihydroartemisinin-piperaquine, artesunate-mefloquine and extended artemether-lumefantrine treatments for malaria in pregnancy on the Thailand-Myanmar border. BMC Medicine. https://doi.org/10.1186/s12916-021-02002-8

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.